Neuroreport · 1997 · 306 citations · 3 references
MedicineNeurosciencePharmacologyBehavioral PharmacologyNeuropharmacologyPsychopharmacologyAnxiety DisordersAnxiolytic PharmacologyAnxiolytic TherapyCannabinoid PharmacologyPsychostimulant PharmacologyAnxiety ResponsesCannabinoid AntagonistsCannabinoid Effects On AnxietyCannabinoid Receptor ModulationCannabinoid Receptor PharmacodynamicsCannabinoid Receptor PharmacologyCannabinoid WithdrawalWithdrawal Symptoms
Animal models have revealed that psychoactive cannabinoids induce both anxiolytic and anxiety-like reactions which are dose- and context-dependent. In the present study we examined the acute actions of the CB1 cannabinoid receptor antagonist SR 141716A in both the defensive withdrawal test and the elevated plus-maze in rats. Acute administration of SR 141716A (0.1, 1 and 3 mg kg-1) induced defensive responses in both anxiety tests, at a dose of 3 mg kg-1. This dose had no effect on horizontal locomotor activity and did not activate the hypothalamus-pituitary-adrenal axis, although several cannabinoid withdrawal-like behavioural symptoms were observed. These results demonstrate that blockade of the endogenous cannabinoid tone might induce anxiety-like responses in rats.
3
Hollister Le · Journal of Ethnopharmacology · 1987 · 498 citations